Liver Fibrosis Market Size in the 7MM is projected to grow at a CAGR of 23.9% by 2034, estimates DelveInsight

DelveInsight's "Liver Fibrosis Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Liver Fibrosis epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Liver Fibrosis therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Liver Fibrosis Market Report
• On January 13, 2026- Madrigal Pharmaceuticals Inc. conducted a phase 2 study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
• On January 09, 2026- Boehringer Ingelheim announced a study is to find out the effect of survodutide on MASH and liver fibrosis. The purpose of the second part is to find out how safe and effective survodutide is in improving liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide.
• DelveInsight's epidemiology model estimates that in 2023, there were approximately 8 million diagnosed prevalent cases of liver fibrosis across the 7MM which are expected to increase by 2034.
• In 2023, the US reported the highest number of liver fibrosis cases among the 7MM, with approximately 4 million, a figure expected to rise by 2034.
• In 2023, Germany reported the highest number of liver fibrosis cases among EU4 and the UK, with approximately 770 thousand cases, followed by Italy and France, with around 620 thousand and 520 thousand cases respectively. Spain had the lowest number, with approximately 360 thousand cases.
• In 2023, Japan reported approximately 1.2 million liver fibrosis cases, a number projected to increase by 2034.
• In Japan, in 2023, cases of MASH/NASH were categorized by severity into F0, F1, F2, F3, and F4 stages. The highest prevalence was observed in the F1 stage, with approximately 240 thousand cases, while the F4 stage had the lowest, around 35 thousand cases.
• In 2023, Germany recorded the highest number of severity-specific NASH/MASH cases among the EU4 and the UK, with approximately 285 thousand cases in the F1 stage and nearly 55 thousand in the F4 stage.
• In 2023, there were approximately 3 million diagnosed prevalent cases of liver fibrosis (=F2 stage) in MASH/NASH across the 7MM, a figure expected to rise by 2034.
• In 2023, Japan reported approximately 240 thousand diagnosed prevalent cases of liver fibrosis (=F2 stage) in MASH/NASH cases, a number projected to increase by 2034.
• The leading Liver Fibrosis Companies such as Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk A/S, Viking Therapeutics, Hepion Pharmaceuticals, Pfizer, HighTide Biopharma, Boston Pharmaceuticals, Rivus Pharmaceuticals, Lipocine, Aligos Therapeutics, MediciNova, NorthSea Therapeutics, Eli Lilly, and others.
• Promising Liver Fibrosis Therapies such as Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, Oltipraz, IDN-6556, ZED1227 and others.

Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Fibrosis Epidemiology Segmentation in the 7MM
• Total Liver Fibrosis Diagnosed Prevalent Cases
• Liver Fibrosis Severity-specific Diagnosed Prevalent Cases
• Total Liver Fibrosis Diagnosed Prevalent Cases (≥F2 Stage) in MASH

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Fibrosis Marketed Drugs
• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
REZDIFFRA (resmetirom), a Thyroid Hormone Receptor-beta (THR-ß) agonist, received US FDA approval in March 2024 for adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2-F3) as an adjunct to diet and exercise, following accelerated approval based on improvements in MASH and fibrosis. Madrigal Pharmaceuticals secured Priority Review, Breakthrough Therapy Designation (BTD), and Fast Track Designation (FTD) from the US FDA for MASH with liver fibrosis, underscoring its therapeutic significance. The company plans a phased European launch starting in Germany in the second half of 2025, pending EMA approval, positioning REZDIFFRA as the first approved MASH liver fibrosis therapy in Europe. Additionally, new two-year data from the MAESTRO-NAFLD-1 trial, released in February 2025, suggest potential benefits in patients with compensated MASH cirrhosis, indicating broader clinical utility.

Liver Fibrosis Emerging Drugs
• Efruxifermin (EFX): Akero Therapeutics
Efruxifermin (EFX), an Fc-FGF21 fusion protein designed to mimic native FGF21 activity, regulates metabolism and mitigates cellular stress. It is currently in three Phase III trials for MASH, with Phase II data showing its potential to reduce liver fat and inflammation, reverse fibrosis (including compensated cirrhosis), and improve metabolic parameters. Akero completed enrolment for the double-blind portion of the Phase III SYNCHRONY Real-World study in January 2025, with results expected in the first half of 2026. The US FDA granted EFX BTD and FTD for NASH, while the EMA awarded it PRIME designation, highlighting its potential as a transformative therapy.

• Denifanstat (TVB-2640): Sagimet Biosciences
Denifanstat, a selective fatty acid synthase (FASN) inhibitor, is in Phase III development for MASH, targeting De Novo Lipogenesis (DNL) to reduce palmitate production. In October 2024, Sagimet Biosciences successfully concluded end-of-Phase II discussions with the US FDA, advancing denifanstat into Phase III trials. The FASCINATE-3 trial focuses on noncirrhotic MASH (F2/F3), while FASCINIT evaluates patients with suspected or confirmed MASLD/MASH.

• Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
Survodutide, a dual GLP-1/glucagon receptor agonist, is in Phase III development for MASH and fibrosis, targeting key metabolic pathways. In October 2024, Boehringer Ingelheim initiated the LIVERAGE trials, including LIVERAGE for MASH with fibrosis and LIVERAGE-Cirrhosis for MASH with cirrhosis. The US FDA granted BTD for noncirrhotic MASH with fibrosis, while the EMA included survodutide in its Priority Medicines (PRIME) scheme for NASH. Additionally, Boehringer Ingelheim and Zealand Pharma received US FDA, underscoring its potential to address the unmet needs in MASH treatment.

• Pegozafermin: 89bio
Pegozafermin, an investigational FGF21 analog developed using glycoPEGylation technology, is designed to activate FGFR1c, 2c, or 3c with the co-receptor ß-Klotho in metabolic tissues, addressing metabolic dysfunctions associated with MASH. In May 2024, 89bio initiated the Phase III ENLIGHTEN-Cirrhosis trial to evaluate its efficacy in MASH patients with compensated cirrhosis. The EMA granted pegozafermin PRIME designation for MASH with fibrosis and compensated cirrhosis, while the US FDA awarded BTD based on positive Phase IIb ENLIVEN trial data, reinforcing its potential as a novel treatment in the evolving MASH landscape.

Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Fibrosis Market Outlook
Liver fibrosis is a pathological consequence of chronic liver injury, characterized by excessive extracellular matrix deposition that disrupts normal hepatic architecture and function. Current therapeutic strategies primarily target underlying etiologies such as viral hepatitis, metabolic dysfunction, and alcohol-related liver disease, with limited direct anti-fibrotic interventions. Among approved treatments, REZDIFFRA (resmetirom), a THR-ß agonist, is the first US FDA-approved therapy for noncirrhotic NASH with moderate to advanced fibrosis, reducing hepatic fat and modulating fibrogenic pathways.

Liver Fibrosis Drugs Market
Liver Fibrosis is being targeted through multiple therapeutic classes, each addressing distinct pathological mechanisms. THR-ß agonists enhance hepatic metabolism and reduce fibrosis by promoting lipid clearance and resolving MASH. FGF21 analogs improve insulin sensitivity, lipid metabolism, and inflammation while attenuating fibrogenesis. GLP-1/glucagon dual agonists regulate metabolic pathways by enhancing glucose homeostasis and reducing hepatic steatosis and fibrosis. FASN inhibitors block de novo lipogenesis, limiting the accumulation of harmful lipids that contribute to fibrotic progression. These pharmacological classes represent a multimodal strategy, targeting metabolic dysfunction, inflammation, and fibrotic pathways to improve liver health and slow disease progression.

Liver Fibrosis Companies
Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk A/S, Viking Therapeutics, Hepion Pharmaceuticals, Pfizer, HighTide Biopharma, Boston Pharmaceuticals, Rivus Pharmaceuticals, Lipocine, Aligos Therapeutics, MediciNova, NorthSea Therapeutics, Eli Lilly, and others.

Scope of the Liver Fibrosis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Liver Fibrosis Companies- Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk A/S, Viking Therapeutics, Hepion Pharmaceuticals, Pfizer, HighTide Biopharma, Boston Pharmaceuticals, Rivus Pharmaceuticals, Lipocine, Aligos Therapeutics, MediciNova, NorthSea Therapeutics, Eli Lilly, and others.
• Liver Fibrosis Pipeline Therapies- Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, Oltipraz, IDN-6556, ZED1227 and others.
• Liver Fibrosis Therapeutic Assessment: Liver Fibrosis Current Marketed and Liver Fibrosis Emerging Therapies
• Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
• Liver Fibrosis Unmet Needs, KOL's views, Analyst's views, Liver Fibrosis Market Access and Reimbursement

From market size to emerging drugs-find it all in our latest report. Read now! @ https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Liver Fibrosis Market Overview at a Glance
4. Liver Fibrosis Methodology
5. Liver Fibrosis Executive Summary
6. Liver Fibrosis Disease Background and Overview
7. Liver Fibrosis Treatment and Management
8. Liver Fibrosis Epidemiology and Patient Population
9. Liver Fibrosis Patient Journey
10. Emerging Liver Fibrosis Therapies
11. Liver Fibrosis Market Analysis
12. Liver Fibrosis KOL Views
13. Liver Fibrosis SWOT Analysis
14. Liver Fibrosis Unmet Needs
15. Liver Fibrosis Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.